The current standard of care treatment for Pompe disease, enzyme replace therapy (ERT), consisting of frequent intravenous infusions of recombinant human GAA (rhGAA), reduces muscle glycogen and can improve muscle function and patient quality of life8–11. Here, GAA is linked to Glycogen storage disease due to acid maltase deficiency.